Five-Year Sustained Response to Nivolumab in Hepatocellular Carcinoma following Serious Immune-Related Hepatitis.

José Leão Mendes, Ana Sofia Spencer, João Cabral Pimentel, Mariana Sardinha, João Boavida Ferreira, Ricardo da Luz

Abstract read

In one paragraph

Article in GE Portuguese journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

José Leão MendesMedical Oncology Department, Unidade Local de Saúde São José, Lisbon, Portugal.

Ana Sofia SpencerMedical Oncology Department, Unidade Local de Saúde Santa Maria, Lisbon, Portugal.

João Cabral PimentelCentro Clínico Académico de Lisboa, Lisbon, Portugal.

Mariana SardinhaMedical Oncology Department, Unidade Local de Saúde São José, Lisbon, Portugal.

João Boavida FerreiraMedical Oncology Department, Unidade Local de Saúde São José, Lisbon, Portugal.

Ricardo da LuzMedical Oncology Department, Hospital Lusíadas Lisboa, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatocellular carcinoma (HCC) holds high cancer mortality worldwide. Immunotherapy-based combination therapy, currently the first-line (1L) standard of care in advanced HCC, has shifted the treatment paradigm concerning both efficacy and safety outcomes. Data on immune-related adverse event surrogacy for efficacy outcomes are mixed. Case Report: We report the case of a 58-year-old male with chronic hepatitis C virus infection who presented with a voluminous shoulder HCC metastasis. Albeit an initial significant biochemical response with 1L sorafenib, progressive disease after 3 months plus a bleeding complication led to treatment discontinuation. Second-line nivolumab, although yielding a rapid clinical and biochemical response, was permanently ceased after 12 weeks due to a grade 3 immune-related hepatitis. Notably, 5 years post-treatment, the patient sustains a major biochemical and radiographic response. Discussion: This case highlights an unusual and sustained response to nivolumab treatment in HCC, following early treatment discontinuation due to severe hepatotoxicity.

Indexed as

Drug-related side effects and adverse reactionsHepatocellular carcinomaImmune checkpoint inhibitorsNivolumabProgression-free survival

Identifiers

PMID41090146

DOI10.1159/000543288

PMCPMC12517671

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.